Can Boeing Shares Reach the 80% Increase of 2013?
For Boeing, last year was a year for positioning, and 2015 appears to be another year for share price growth, although not anything like 2013.
For Boeing, last year was a year for positioning, and 2015 appears to be another year for share price growth, although not anything like 2013.
Despite trouble at its Fiat unit and the fact that Chrysler has no real footprint outside the United States, company sales continue to outpace the industry.
Here are this past week's five analyst picks under $10 with colossal upside featured by 24/7 Wall St.
Here is a look at the initial public offerings on the schedule for the coming week, including three holdovers from last week.
Needless to say, when a market has an almost six-year run like we have seen, insiders are itching to take some money off the table.
Logically, it seems that as they stock market zooms higher, insiders who want to buy stock would wait until a pullback to add new capital.
Last week, the total number of rigs drilling for oil in the United States fell, according to the latest Baker Hughes North American Rotary Rig Count.
The latest study by the National Highway Traffic Safety Administration shows that drunk driving has declined by nearly a third since 2007.
Income tax refund levels are so strong this year that they might join lower gasoline prices to further improve consumer spending.
The ongoing decline of the U.S. Postal Service showed again when it posted results for the final quarter of 2014.
Moody's, the credit research service, has expressed doubt about the future of Greek debt.
ThinkstockFebruary 6, 2015: Here are four stocks among the 45 equities making new 52-week lows today. Pandora Media Inc. (NYSE: P) dropped about 22% on Friday to establish a new 52-week low at $14.33…
thinkstockFebruary 6, 2015: Markets opened mixed on Friday following the monthly report on unemployment that showed the rate rising to 5.7%, new jobs growing faster than expected, and hourly wage growth up 0.5%. Equities…
Coal prices in the United States have reached a six-year low and could fall further in 2015. The situation is little better internationally.
Credit Suisse downgraded Gilead Sciences to Neutral and lowered its price target, citing increased competition for hepatitis C drugs.